Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258074 · ClinicalTrials.gov registry record · Phase 2
The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT02258074 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 205 participants.
The verdict
NCT02258074, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.
Interventions
- DRUG Nicotinamide
- DRUG Lanthanum Carbonate
- DRUG Placebo (for Nicotinamide)
- DRUG Placebo (for lanthanum carbonate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258074
The ClinicalTrials.gov registry entry for NCT02258074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nicotinamide is the first listed.
NCT02258074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258074 about?
NCT02258074 is a clinical study titled "The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE". The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.
What is the current status of trial NCT02258074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2015-03. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02258074?
The interventions under investigation include: Nicotinamide (DRUG), Lanthanum Carbonate (DRUG), Placebo (for Nicotinamide) (DRUG), Placebo (for lanthanum carbonate) (DRUG).
Who is sponsoring clinical trial NCT02258074?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.